HAMs demonstrate favorable therapeutic efficacy by decreasing the production of inflammatory factors (TNF-α, IL-6, and IL-1β), restoring the intestinal barrier, and modulating the gut microbiota in an IBD mouse model (Figure 1). Here, TNF is linked to inflammatory bowel disease.